Walmart, the largest retailer in the United States, has agreed to a $3.1 billion settlement to resolve thousands of lawsuits related to the dispensing of powerful prescription opioids at its pharmacies. This settlement aims to provide funds for addiction treatment and drug education programs in communities nationwide. The company, however, denies any wrongdoing or liability in the matter.
The agreement follows similar settlements from other major pharmacy chains, CVS Health and Walgreens, which each committed to pay around $5 billion. With these latest agreements, the total amount from Walmart, CVS, and Walgreens will reach approximately $13.1 billion, contributing to an overall opioid litigation settlement sum exceeding $50 billion.
The majority of the $3.1 billion from Walmart is expected to be paid over the next year once the settlement is finalized. The company stated that this resolution is in the best interest of all parties and will provide significant aid to communities, reaching state and local governments faster than previous nationwide opioid settlements. The settlement requires Walmart to comply with oversight measures, prevent fraudulent prescriptions, and flag suspicious ones.
While Walmart maintains it has meritorious defenses and that its pharmacies dispensed materially fewer and less potent opioids compared to other major chains, it views this settlement as a cooperative resolution. The company had accrued a liability of approximately $3.3 billion during fiscal year 2023 for this and other opioid-related settlements, with approximately $2.8 billion of that remaining to be paid in the third quarter of fiscal year 2024 as the State Settlement Framework became effective on September 6, 2023.
